ArticleClinical transplantation2020
Induction immunosuppression and the risk of incident malignancies among older and younger kidney transplant recipients: A prospective cohort study.
Article in Clinical transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation.World journal of transplantation · 2026Review
- Clinical Equipoise and Unimproved Outcomes following Posttransplant Cutaneous Squamous Cell Carcinoma.Kidney international reports · 2026Article
- Practical Guide to Address Common Myths in the Pre- and Post-kidney Transplant Management of the Elderly Patient with Cancer: An Opinion Paper.Transplantation direct · 2026Article
- Review
- Risk Factors for the Development of Malignancies Post-Transplantation in Kidney Transplant Recipients.Biomedicines · 2025Article
- Necessity of induction agent modification for old age kidney transplant recipients.Kidney research and clinical practice · 2025Article
- Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression.Journal of clinical medicine · 2024Article
- A case controlled study of risk factors for metastatic squamous cell carcinoma in organ transplant recipients: single academic medical center.Archives of dermatological research · 2024Article
- Impact of Immunosenescence in Older Kidney Transplant Recipients: Associated Clinical Outcomes and Possible Risk Stratification for Immunosuppression Reduction.Drugs & aging · 2024Review
- Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Posttransplant Diabetes Mellitus and Immunosuppression Selection in Older and Obese Kidney Recipients.Kidney medicine · 2022Article
- Immunosuppression Considerations for Older Kidney Transplant Recipients.Current transplantation reports · 2021Article
- Rejection in Liver Transplantation Recipients.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundOlder (≥65) KT recipients differ from their younger counterparts in their immune response to immunosuppression (IS) and may have a different risk of malignancy after receiving induction.
methodsWe identified 66 700 adult KT recipients treated with anti-thymocyte globulin (ATG) (n = 40 443) or interleukin-2 receptor antagonist (IL-2RA) (n = 26 327) induction (1/1/1999-12/31/2014) using USRDS/Medicare data. We estimated the risk of first-diagnosed post-KT malignancy associated with induction (ATG vs. IL-2RA) using Cox proportional hazard models. We then tested whether these risks differed between older and younger recipients (Wald test for interaction). Models incorporated inverse probability of treatment weights to adjust for confounders.
resultsThe 3-year cumulative incidences of any diagnosed malignancy were 11.5%. ATG was associated with a higher malignancy risk (HR = 1.12, 95%CI:1.06-1.18). This association differed (p
conclusionsCompared with IL-2RA induction, ATG was associated with elevated post-KT malignancy risk but only among younger recipients. Transplant centers may need to tailor induction IS for younger recipients to mitigate malignancy risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.